BCLI_OUT_1 [2025-04-28 11:51:47 -0400] 5990 Bytes | 1559 tokens | Cum: 1559 tkns (19.49% of 8k)
==========================================================================

Listen up, partner—it's 11:51 AM on Mon Apr 28, 2025, and I’m revved up about Brainstorm Cell Therapeutics (BCLI), climbing from $0.9750 to $1.19. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Brainstorm Cell Therapeutics (BCLI)
IPO: 2003-10-07 (21 Years Ago)
Market Cap: $6,844,994
Shares Outstanding: 6,520,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Here’s a list of headlines for Brainstorm Cell Therapeutics:

Apr-10-25 07:30AM - BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn in ALS
Apr-01-25 03:01AM - Brainstorm Cell Therapeutics Inc (BCLI) Q4 2024 Earnings Call Highlights: Navigating Financial ...
Mar-31-25 11:41PM - Q4 2024 Brainstorm Cell Therapeutics Inc Earnings Call
Mar-31-25 11:41PM 10:48AM - Brainstorm Cell Therapeutics Inc. (BCLI) Q4 2024 Earnings Call Transcript
Mar-31-25 11:41PM 07:00AM - BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
Mar-26-25 08:15AM - BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
Mar-24-25 07:00AM - BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update
Dec-30-24 08:00AM - BrainStorm Issues 2024 Letter to Shareholders
Dec-09-24 07:00AM - BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update
Dec-03-24 07:00AM - BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
Dec-02-24 07:00AM - BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024
Nov-14-24 04:30PM - BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Nov-11-24 06:00AM - BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn Phase 3b Trial Manufacturing
Oct-30-24 06:00AM - BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Oct-28-24 06:00AM - BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn Expanded Access Program at 2024 Annual NEALS Meeting
Oct-07-24 07:00AM - BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn Trial at the 2024 Maxim Healthcare Virtual Summit
Sep-24-24 06:00AM - BrainStorm Cell Therapeutics Announces Presentations on NurOwn at 2024 Annual NEALS Meeting
Sep-16-24 12:07PM - Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Aug-14-24 07:05AM - BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Aug-07-24 06:00AM - BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update
Jul-24-24 08:30AM - BCLI Update - Progress Supports Our 10x Plus Value Range Potential
Jul-01-24 06:00AM - BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-26T12:15:00Z - BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
B2 - 2025-02-21T18:00:00Z - Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight
B3 - 2024-04-09T10:05:24Z - Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
B4 - 2024-03-25T18:44:08Z - Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
B5 - 2024-01-30T18:18:27Z - Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B6 - 2023-12-27T19:11:57Z - Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Brainstorm Cell Therapeutics (BCLI).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

BCLI_OUT_3 [2025-04-28 11:51:47 -0400] 818 Bytes | 197 tokens | Cum: 1758 tkns (21.98% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/25/03/n44491946/brainstorm-cell-therapeutics-granted-compliance-extension-from-nasdaqBrainStorm Cell Therapeutics has been granted an extension by Nasdaq to regain compliance with certain continued listing standards by June 30, 2025. The company is committed to executing its compliance plan and advancing its clinical programs to deliver value to patients and shareholders.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_5 [2025-04-28 11:51:48 -0400] 1012 Bytes | 290 tokens | Cum: 2050 tkns (25.62% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-10T11:30:00Z - BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurO...
A2 - 2025-04-10T11:32:56Z - Brainstorm Cell Therapeutics (BCLI) Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial ...
A3 - 2025-03-31T14:48:40Z - Brainstorm Cell Therapeutics Inc. (BCLI) Q4 2024 Earnings Call Transcript...
A4 - 2025-03-31T11:34:07Z - BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Updat...
A5 - 2025-03-31T11:32:04Z - BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Updat...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

BCLI_OUT_7 [2025-04-28 11:51:49 -0400] 1183 Bytes | 321 tokens | Cum: 2373 tkns (29.66% of 8k)
==========================================================================

Showing A1 (chunk 1 of 9): A1:
**BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS - Brainstorm Cell (NASDAQ:BCLI)**Date: 2025-04-10Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/pressreleases/25/04/n44731402/brainstorm-cell-therapeutics-submits-ind-amendment-to-fda-paving-the-way-for-phase-3b-trial-of-nurNEW YORK, April 10, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. BCLI, a leading biotechnology company developing cutting-edge cell therapies for neurodegenerative diseases, today announced the submission of an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA) for NurOwn®, the company's autologous mesenchymal stem cell therapy for amyotrophic lateral sclerosis (ALS). This important milestone sets the stage for the initiation of BrainStorm's highly anti

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_9 [2025-04-28 11:51:50 -0400] 1181 Bytes | 266 tokens | Cum: 2641 tkns (33.01% of 8k)
==========================================================================

Showing A1 (chunk 2 of 9): cipated Phase 3b clinical trial, which has been designed in collaboration with the FDA under a Special Protocol Assessment (SPA). The SPA agreement confirms that the Phase 3b trial design and statistical analysis plan is in line with the FDA's expectations, validating its potential to support a future Biologics License Application (BLA). The company now anticipates a swift regulatory review of the IND, clearing the way for the trial's launch.

"The submission of this IND amendment, together with the FDA's agreement on our trial design under the SPA, represents a major step toward bringing NurOwn to ALS patients," said Chaim Lebovits, CEO of BrainStorm Cell Therapeutics. "We are optimistic about a rapid review and are eager to initiate our Phase 3b study, which we are undertaking to support regulatory approval."

The Phase 3b trial is expected to enroll approximately 200 ALS participants

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_11 [2025-04-28 11:51:50 -0400] 1181 Bytes | 252 tokens | Cum: 2895 tkns (36.19% of 8k)
==========================================================================

Showing A1 (chunk 3 of 9): and will be conducted in two parts. In Part A, patients will receive three doses of either NurOwn or placebo over a 24-week double-blind period. Following this, all participants - including those initially in the placebo group - will have the opportunity to transition to an open-label extension (Part B), receiving three additional doses of NurOwn over another 24 weeks. The trial's primary efficacy endpoint will assess changes in ALSFRS-R scores from baseline to week 24, comparing disease progression between the NurOwn and placebo groups. The successful completion of Part A will position BrainStorm for a BLA submission, accelerating NurOwn's path to potential approval.

ALS remains a devastating disease with limited therapeutic options, and BrainStorm is committed to working closely with regulatory agencies, clinical investigators, and the ALS community to ensure the rapid and rigorous ev

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_13 [2025-04-28 11:51:51 -0400] 1183 Bytes | 270 tokens | Cum: 3167 tkns (39.59% of 8k)
==========================================================================

Showing A1 (chunk 4 of 9): aluation of NurOwn. The company will provide updates as the FDA review progresses.

About NurOwn®

The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

About Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. is

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_15 [2025-04-28 11:51:52 -0400] 1182 Bytes | 270 tokens | Cum: 3439 tkns (42.99% of 8k)
==========================================================================

Showing A1 (chunk 5 of 9): a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). Brainstorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). Brainstorm completed under an investigational new drug application a Phase 2 open-l

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_17 [2025-04-28 11:51:53 -0400] 1181 Bytes | 265 tokens | Cum: 3706 tkns (46.33% of 8k)
==========================================================================

Showing A1 (chunk 6 of 9): abel multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS) and was supported by a grant from the National MS Society (NMSS).

Notice Regarding Forward-Looking Statements

-- disclaimer trimmed -- that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), ADCOM meeting related to NurOwn, the timing of a PDUFA action date for the BLA for NurOwn, the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_19 [2025-04-28 11:51:53 -0400] 1181 Bytes | 266 tokens | Cum: 3974 tkns (49.68% of 8k)
==========================================================================

Showing A1 (chunk 7 of 9): "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annua

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_21 [2025-04-28 11:51:54 -0400] 1181 Bytes | 259 tokens | Cum: 4235 tkns (52.94% of 8k)
==========================================================================

Showing A1 (chunk 8 of 9): l report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

CONTACTS

Michael Wood

Phone: +1 646-597-6983

[email protected]

Logo - https://mma

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_23 [2025-04-28 11:51:55 -0400] 841 Bytes | 231 tokens | Cum: 4468 tkns (55.85% of 8k)
==========================================================================

Showing A1 (chunk 9 of 9): .prnewswire.com/media/1166536/BrainStorm_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-submits-ind-amendment-to-fda-paving-the-way-for-phase-3b-trial-of-nurown-in-als-302425558.html

SOURCE BrainStorm Cell Therapeutics Inc.

BCLIBrainstorm Cell Therapeutics Inc$1.196.77%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum3.76Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_25 [2025-04-28 11:51:55 -0400] 1079 Bytes | 286 tokens | Cum: 4756 tkns (59.45% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K Item 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

The following discussion and analysis should be read in conjunction with our audited CONS financial statements and the related notes that appear elsewhere in this Annual Report ...

S2 - 2025-03-31 8-K Item 2.02. Results of Oper and Fin Cond.

On March 31, 2025, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the year ended December 31, 2024. The full text of the press release is being furnished as Exhibit 99.1 to ...

S3 - 2025-03-31 8-K Item 1.01 Entry into a Material Definitive Agrmt.

Warrant Inducement Agrmt

On March 31, 2025, Brainstorm Cell Therapeutics, Inc. (the Company) entered into an inducement offer (the Agrmt) with a certain accredited and institutional holder (the Holder) to exercise ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BCLI_OUT_27 [2025-04-28 11:51:56 -0400] 1181 Bytes | 249 tokens | Cum: 5007 tkns (62.59% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with our audited consolidated financial statements and the related notes that appear elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled Risk Factors and elsewhere in this Annual Report on Form 10-K. For further information regarding forward-looking statements, please refer to the Special Note Regarding Forward-Looking Statements at the beginning of Part I of this Annual Report on Form 10-K.

Company Overview

We are a leading biotechnol

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_29 [2025-04-28 11:51:56 -0400] 1181 Bytes | 253 tokens | Cum: 5262 tkns (65.77% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ogy company engaged in the development of best-in-class autologous cellular therapies derived from a patients own bone marrow cells for the treatment of neurodegenerative diseases. We hold the rights to clinical development and commercialization of the NurOwn technology platform through an exclusive, worldwide licensing agreement (see details herein). NurOwn has received Fast Track designation from the FDA in ALS and has additionally been granted Orphan Drug Status by the FDA and the EMA.

We are committed to bring innovative central nervous system (CNS) adult stem cell therapies to the market to improve the lives of patients with debilitating neurodegenerative diseases. As a leader in CNS regenerative cellular medicines, we are leveraging NurOwn, its proprietary autologous mesenchymal stem cell platform technology, a strong and expanded intellectual property portfolio, as well as manufa

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_31 [2025-04-28 11:51:57 -0400] 1181 Bytes | 264 tokens | Cum: 5528 tkns (69.10% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): cturing and commercialization capabilities, to address growing unmet medical needs across a broad range of neurodegenerative disorders, such as ALS, PMS, AD and other neurodegenerative diseases. NurOwn uses proprietary cell culture conditions to induce MSCs to secrete high levels of multiple neurotrophic factors to modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function.

Results of Operations

For the period from inception (September 22, 2000) until December 31, 2024, we did not generate any revenues from operations. In addition, we incurred operating costs and expenses of approximately $11,623,000 during the year ended December 31, 2024.

Research and Development, net

Our business model calls for significant investments in research and development. Our research and development expenditures, net in the year ended D

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_33 [2025-04-28 11:51:58 -0400] 1181 Bytes | 323 tokens | Cum: 5853 tkns (73.16% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): ecember 31, 2024 were $4,651,000, a decrease of $6,095,000 compared to $10,746,000 for the year ended December 31, 2023.

This decrease is due to: (i) a decrease of $2,450,000 in connection with costs related to the Phase 3 Clinical Trials; (ii) a decrease of $2,028,000 in connection with materials and clean room facilities; (iii) a decrease of $1,476,000 for costs related to payroll expenses and costs related to stock-based compensation expenses and (iv) a decrease of $141,000 in connection with patens, depreciation and rent and other costs.

General and Administrative

General and administrative expenses for the years ended December 31, 2024 and 2023 were $7,042,000 and $10,693,000, respectively. The decrease of $3,651,000 in general and administrative expenses is mainly due to: (i) a decrease of $2,841,000 in in payroll expenses and (ii) a decrease of $844,000 in the travel costs, con

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_35 [2025-04-28 11:51:59 -0400] 1181 Bytes | 297 tokens | Cum: 6152 tkns (76.90% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): sultants, rent costs, depreciation and costs of our investor relations and public relations activities. This decrease was partially offset by an increase of $34,000 in stock-based compensation expenses and stock costs.

Financial Expenses

Financial expense for the year ended December 31, 2024 was $77,000 as compared to financial expenses of $447,000 for the year ended December 31, 2023 due to conversion exchange rates that was offset by financial expenses of $169 related to issuance costs of warrants that were classified as a liability in 2023.

Net Loss

Net loss for the year ended December 31, 2024 was $11,623,000, as compared to a net loss of $17,192,000 for the year ended December 31, 2023. Net loss per share for the year ended December 31, 2024 and December 31, 2023 was $2.31 and $6.00, respectively.

The weighted average number of shares of Common Stock used in computing basic and

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_37 [2025-04-28 11:51:59 -0400] 790 Bytes | 202 tokens | Cum: 6356 tkns (79.45% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): diluted net loss per share for the year ended December 31, 2024 was 5,021,798 compared to 2,871,729 for the year ended December 31, 2023.

The increase in the weighted average number of shares of Common Stock used in computing basic loss per share for the year ended December 31, 2024 was due to: (i) the issuance of shares to employees and directors; (ii) issuance and sale of shares of Common Stock pursuant to the Distribution Agreement and (iii) issuance of shares for private placement.

Additional...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCLI_OUT_39 [2025-04-28 11:52:06 -0400] 5916 Bytes | 1544 tokens | Cum: 7902 tkns (98.78% of 8k)
==========================================================================

This is our set of metrics for Brainstorm Cell Therapeutics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+-----------------------+
| Volume: 310,421 | Perf Month: -14.07% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 143.77K | Perf Quarter: -42.86% | Short Float: 6.84% | ROE: - |
+---------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 6.09 | Index: - | Short Ratio: 2.41 | ROI: - |
+---------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 54.31 | Market Cap: 7.57M | Short Interest: 0.35M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 0.13 | Shs Outstand: 6.14M | Beta: 0.39 | EPS Surprise: -36.84% |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA20: 16.43% | Shs Float: 5.07M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA50: -13.64% | Inst Own: 6.32% | Sales past 5Y: 0.00% | Earnings: Mar 31 BMO |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA200: -54.34% | Insider Own: 22.32% | Employees: 27 | |
+---------------------+-----------------------+------------------------+-----------------------+
| Perf Week: 34.88% | Insider Trans: 0.00% | Debt/Eq: - | |
+---------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading by Brainstorm Cell Therapeutics officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -14228000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.1897
Average Volume: 387468.35
30-Day High: 1.26
30-Day Low: 0.7624

[Detailed Financials: Q3 2024]
- Total Assets: $2,025,000.00
- Total Liabilities: $8,082,000.00
- Total Equity: $-6,057,000.00
- Current Assets: $364,000.00
- Current Liabilities: $7,082,000.00

[Income Statement: Q3 2024]
- Revenue: N/A
- Net Income: $-2,708,000.00
- Gross Profit: N/A
- Operating Income: $-3,048,000.00
- Earnings Per Share (EPS): -0.51

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-3,299,000.00

[Detailed Financials: Q2 2024]
- Total Assets: $5,683,000.00
- Total Liabilities: $9,210,000.00
- Total Equity: $-3,527,000.00
- Current Assets: $3,816,000.00
- Current Liabilities: $7,691,000.00

[Income Statement: Q2 2024]
- Revenue: N/A
- Net Income: $-2,541,000.00
- Gross Profit: N/A
- Operating Income: $-2,982,000.00
- Earnings Per Share (EPS): -0.04

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $0.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Brainstorm Cell Therapeutics (BCLI).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Brainstorm Cell Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because BCLI is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for BCLI.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, BCLI could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect BCLI to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Brainstorm Cell Therapeutics.

11) ETHICAL_RATING[]
Rate Brainstorm Cell Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Brainstorm Cell Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

BCLI_IN_41 [2025-04-28 11:52:06 -0400] 126 Bytes | 29 tokens | Cum: 8168 tkns (102.10% of 8k)
==========================================================================

====================================
[2025-04-28 11:52:06] # Analysis Completed
Elapsed Time: 20.85 seconds